Clinical trials: Type 2 Diabetes (T2D)
Type II Diabetes Mellitus, Dyslipidemia
Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
This is a sixteen-week double-blind active-controlled follow-on and 28-week single-blind extension study for patients who participated in study NK-104-305.
- Trial name
- NCT00344370
- Testing
- Pitavastatin, Atorvastatin
- Where
- 35 sites in Denmark, Germany and 4 more
- Volunteers
- 214 people
- Sponsor
- Kowa Research Europe
Type 2 Diabetes Mellitus (T2DM), Type2Diabetes
Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)
This registry is designed to collect long-term data and support ongoing post-market surveillance of real-world data for the Endogenex System.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Type2Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
- Trial name
- NCT07197775
- Where
- 4 sites in United States, Australia
- Volunteers
- 500 people
- Sponsor
- Endogenex, Inc.
Diabetes
Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus
The present study is an exploratory trial to establish a feasible DLW (doubly labelled water) protocol for implementation in clinical trials conducted at Profil Institut für Stoffwechselforschung, investigating treatment options…
- Trial name
- DLW (NCT02518581)
- Testing
- Doubly labelled water method
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic…
- Trial name
- NCT01167881
- Testing
- BI 10773, Glimepiride
- Where
- 182 sites in United States, Argentina and 21 more
- Volunteers
- 1,549 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine.
- Trial name
- AWARD-9 (NCT02152371)
- Testing
- Dulaglutide, Insulin Glargine, Metformin
- Where
- 40 sites in United States, Czechia and 5 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Insulin Glargine Combination Therapies in Type II Diabetics
To compare efficacy of combination therapy of insulin glargine plus glimepiride and metformin versus 2 injections insulin monotherapy with premixed insulin NPH 30/70 bid in terms of change of HbA1c (baseline to endpoint) to show…
- Trial name
- LAPTOP (NCT00783744)
- Testing
- Insulin Glargine, Glimepiride, Metformin
- Where
- 10 sites in Austria, Finland and 8 more
- Volunteers
- 375 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
- Trial name
- NCT00082381
- Testing
- Exenatide (AC2993), Insulin glargine
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 551 people
- Sponsor
- AstraZeneca
Type 1 Diabetes, Type2diabetes
Liom Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)
This is a single-centre, multiple cohort, open study.
- Trial name
- NCT06272136
- Testing
- Clinical Demo 2.0
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Liom Health AG
Type 2 Diabetes
Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls
To evaluate 18F-AV-133 imaging of the pancreas in patients with early type 2 diabetes, late type 2 diabetes, subjects with pre-diabetes and in healthy overweight/obese control subjects.
- Trial name
- NCT01710371
- Testing
- 18F-AV-133, 10% Arginine Hydrochloride-R-Gene 10
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Type 2 Diabetes
Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes
The purpose of this study is to assess the efficacy response of rivoglitazone HCl on the change in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.
- Trial name
- NCT00575471
- Testing
- Rivoglitazone HCl
- Where
- 3 sites in Japan
- Volunteers
- 250 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Primary Objective: To demonstrate the non-inferiority of Sotagliflozin 400 milligrams (mg) compared to Glimepiride on hemoglobin A1c (HbA1c) reduction at Week 52 in participants with Type 2 Diabetes (T2D) who have inadequate…
- Trial name
- SOTA-GLIM (NCT03332771)
- Testing
- Sotagliflozin (SAR439954), Glimepiride, Metformin
- Where
- 142 sites in United States, Bulgaria and 2 more
- Volunteers
- 954 people
- Sponsor
- Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
This is an active- and placebo-controlled, single-site, four-part trial of MK-1092 in healthy adult participants, in participants with type 1 diabetes mellitus (T1DM), and in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03170544
- Testing
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus…
- Trial name
- NCT02057172
- Testing
- HM11260C, liraglutide
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in South Africa, Europe and North America. The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing…
- Trial name
- BEGIN™ (NCT01068665)
- Testing
- insulin degludec, insulin glargine
- Where
- 116 sites in United States, Canada and 6 more
- Volunteers
- 460 people
- Sponsor
- Novo Nordisk A/S
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Type 2 Diabetes Mellitus
A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment
The primary objective of this study is to compare the pharmacokinetics of ASP1941 in type 2 diabetes mellitus patients with normal renal function and those with mild or moderate renal impairment.
- Trial name
- NCT01097681
- Testing
- ASP1941
- Where
- 2 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus, Type 2, Cancer
Epidemiologic Study Of Diabetes And Cancer Risk
The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes along with the assessment…
- Trial name
- NCT02958995
- Testing
- No Intervention
- Volunteers
- 2,738,161 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Primary Objective: To evaluate the efficacy of fixed dose combination of glimepiride and metformin (AMARYL M 1/250mg) in comparison with glimepiride (AMARYL) alone in terms of glycemic control as reflected by HbA1c during a…
- Trial name
- NCT01457911
- Testing
- Glimepiride and Metformin hydrochloride combination (HOE490), Glimepiride (HOE490)
- Where
- 22 sites in China
- Volunteers
- 244 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes
This study is conducted in Europe. The aim of the study was to evaluate the safety and efficacy of biphasic insulin aspart 30 (NovoMix® 30) when switching to a modern premix insulin analogue treatment compared to previous insulin…
- Trial name
- NCT01536639
- Testing
- biphasic insulin aspart 30
- Where
- Slovakia
- Volunteers
- 454 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.